recombin
felin
interferon
omega
immunomodul
commonli
use
felin
retrovir
infect
de
mari
et
al
et
al
gil
et
al
produc
recombin
protein
mean
baculoviru
express
vector
contain
felin
interferon
omega
sequenc
ueda
et
al
baculoviru
replic
silkworm
permit
product
glycosyl
molecul
purif
use
therapeut
ueda
et
al
recommend
protocol
base
cycl
daili
subcutan
administr
mukg
begin
respect
day
follow
initi
vitro
studi
truyen
schultheiss
sever
author
perform
vivo
trial
order
assess
clinic
immun
properti
action
cat
natur
infect
felin
leukemia
viru
felv
coinfect
felv
felin
immunodefici
viru
fiv
describ
show
compound
induc
import
clinic
improv
increas
surviv
time
treat
cat
de
mari
et
al
anoth
group
author
report
improv
clinic
condit
retrovir
infect
cat
although
minor
chang
observ
paramet
hypergammaglobulinemia
ratio
provir
load
viremia
et
al
thu
overal
improv
innat
immun
suspect
et
al
recent
group
report
addit
improv
clinic
sign
also
induc
reduct
concurr
viral
shed
name
herpesviru
coronaviru
parvoviru
caliciviru
particularli
relev
shelter
medicin
attempt
understand
immun
pathway
underli
therapeut
action
also
evalu
effect
compound
acut
phase
protein
app
natur
retrovir
infect
cat
confirm
potenti
innat
immun
respons
despit
clinic
benefit
licens
protocol
natur
retrovirusinfect
cat
costlimit
case
altern
protocol
investig
trial
describ
use
lower
oral
dose
variou
condit
chronic
gingivostomat
hennet
et
al
leal
et
al
oral
protocol
recent
propos
natur
fivinfect
cat
base
daili
oral
administr
mucat
consecut
day
similar
way
licens
protocol
reveal
signific
clinic
improv
treat
cat
without
relev
chang
hematolog
serum
biochemistri
serum
protein
electrophoresi
contrast
licens
protocol
app
appar
differ
mechan
action
two
protocol
agreement
previou
author
suggest
oromucos
interferon
ifn
therapi
seem
act
differ
mechan
parenter
protocol
tovey
therefor
licens
protocol
increas
app
seem
denot
potenti
innat
immun
respons
leal
et
al
oral
protocol
immun
mechan
underli
observ
clinic
improv
remain
unclear
academ
immun
system
divid
two
gener
part
nonspecif
innat
respons
specif
acquir
immun
kennedi
interact
order
maintain
compet
immun
system
achiev
product
releas
differ
cytokin
mediat
immun
respons
distinct
function
includ
activ
proinflammatori
antiinflammatori
pathway
day
kennedi
tizard
tizard
spite
fact
cytokin
pleiotrop
part
immun
system
character
differ
cytokin
pattern
roitt
delv
instanc
tumor
necrosi
factor
tnf
proinflammatori
cytokin
strongli
involv
innat
immun
respons
potenti
nonspecif
pathway
acut
phase
respons
apr
fever
ceron
et
al
paltrinieri
tizard
concern
acquir
immun
pathway
strongli
relat
cellular
immun
respons
subset
activ
locksley
scott
pedersen
et
al
tizard
vancott
et
al
humor
antibodi
respons
subset
associ
product
barnard
et
al
osborn
et
al
pedersen
et
al
roitt
delv
romagnani
et
al
felin
medicin
particularli
fiv
sever
studi
perform
cell
cultur
also
experiment
infect
cat
order
character
cytokin
profil
infect
kipar
et
al
lawrenc
et
al
lerner
et
al
liang
et
al
linenberg
deng
tompkin
tompkin
wood
et
al
despit
fact
clear
shift
respons
fiv
infect
retroviru
induc
cytokin
dysregul
alter
cytokin
transcript
lead
inadequ
innat
cellmedi
immun
respons
pathogen
kipar
et
al
levi
et
al
tompkin
tompkin
author
knowledg
studi
vivo
perform
order
assess
cytokinebas
immunolog
pathway
underli
clinic
improv
restor
control
pathogen
induc
therapi
therefor
studi
aim
evalu
antivir
immunomodulatori
properti
monitor
chang
viremia
provir
load
blood
cytokin
profil
natur
fivinfect
cat
receiv
oral
subcutan
therapi
biolog
sampl
use
studi
collect
natur
fivinfect
cat
previous
enrol
two
past
work
group
leal
et
al
detail
cat
live
anim
shelter
receiv
licens
protocol
sc
group
cat
admit
refer
veterinari
teach
hospit
faculti
veterinari
medicin
univers
lisbon
receiv
oral
protocol
po
group
follow
protocol
previous
describ
leal
et
al
anim
monitor
submit
blood
collect
therapi
respect
sc
po
group
procedur
approv
committe
ethic
anim
welfar
faculti
veterinari
medicin
univers
lisbon
cebea
fmvulisboa
similar
studi
previou
publish
leal
et
al
singlearm
trial
polici
appli
group
mean
paramet
valu
set
baselin
taken
individu
control
cat
specifi
time
point
whole
blood
collect
rna
protect
tube
rnaprotect
anim
blood
tube
qiagen
accord
manufactur
instruct
mrna
extract
use
specif
kit
rneasi
protect
anim
blood
kit
qiagen
thereaft
cdna
synthes
use
transcriptor
high
fidel
roch
follow
manufactur
instruct
use
templat
realtim
quantit
polymeras
chain
reaction
qpcr
primer
use
gene
publish
literatur
respect
author
sequenc
present
tabl
despit
dnase
step
perform
rna
extract
order
preclud
genom
dna
amplif
primer
cover
put
exonexon
junction
optim
experi
effici
assess
amplif
system
previous
perform
data
shown
primer
obtain
commerci
manufactur
stab
vida
portug
rel
express
cytokin
quantifi
use
miner
softwar
http
wwwminerewindupinfo
follow
comput
algorithm
quantit
realtim
pcr
system
zhao
et
al
betaactin
set
housekeepingrefer
gene
tabl
realtim
qpcr
perform
use
stepon
plu
realtim
analyz
appli
biosystem
pcr
assay
compris
reaction
primer
final
concentr
nm
cdna
steril
water
sybr
appli
biosystem
total
volum
per
reaction
thermocycl
condit
consist
initi
denatur
min
follow
cycl
amplif
anneal
min
final
melt
curv
stage
consist
min
follow
ramp
rate
heat
sampl
ramp
rate
melt
curv
obtain
pcr
use
verifi
specif
amplicon
time
point
whole
blood
also
collect
edta
tube
centrifug
g
minut
obtain
plasma
subsequ
frozen
use
plasma
level
measur
specif
elisa
kit
follow
manufactur
instruct
sunr
biotechnolog
compani
order
assess
provir
load
dna
extract
whole
blood
use
specif
kit
dneasi
blood
tissu
qiagen
follow
manufactur
instruct
dna
store
use
templat
provir
load
quantif
realtim
pcr
take
account
major
preval
fivsubtyp
b
southern
europ
duart
tavar
duart
et
al
sampl
screen
subtyp
primer
use
fiv
subtyp
gag
gene
previous
publish
present
tabl
leutenegg
et
al
fiv
b
subtyp
gag
gene
nucleotid
sequenc
avail
genbank
access
number
align
identif
conserv
region
use
specif
softwar
clc
main
workbench
primer
chosen
use
primer
express
softwar
appli
biosystem
visual
inspect
multipl
align
realtim
qpcr
perform
use
stepon
plu
realtim
analyz
appli
biosystem
fifti
nanogram
dna
templat
use
total
volum
compris
taqman
pcr
master
mix
appli
biosystem
optim
differ
primer
probe
concentr
perform
fivb
system
final
concentr
nm
primer
nm
probe
use
fiva
system
nm
primer
nm
probe
use
absolut
quantif
assess
realtim
pcr
use
respect
standard
curv
base
tenfold
dilut
posit
control
fivb
subtyp
previous
publish
plasmid
use
duart
et
al
fiva
purifi
amplicon
obtain
fivpetaluma
crfk
infect
cell
use
fiva
subtyp
thermocycl
condit
consist
initi
denatur
min
follow
five
cycl
cycl
fivb
subtyp
thermocycl
condit
began
initi
denatur
min
follow
cycl
viremia
quantif
viral
rna
extract
plasma
sampl
previous
obtain
centrifug
blood
collect
edta
tube
g
minut
use
specif
kit
qiamp
ultrasen
viru
kit
plasma
viral
rna
store
use
templat
realtim
qpcr
similarli
provir
load
stepon
plu
realtim
analyz
appli
biosystem
use
onestep
realtim
qpcr
perform
use
ng
rna
total
volum
reaction
use
onestep
pcr
kit
mytaq
onestep
rtpcr
kit
take
account
proviru
subtyp
result
respect
system
appli
assess
concurr
viremia
level
concentr
primer
probe
use
thermocycl
condit
use
onestep
realtim
qpcr
similar
previous
describ
proviru
addit
initi
step
reversetranscript
min
begin
measur
paramet
two
group
compar
use
mannwhitneywilcoxon
test
independ
sampl
comparison
end
begin
therapi
group
carri
mannwhitneywilcoxon
test
pair
sampl
appropri
small
sampl
size
correct
signific
level
set
descript
statist
analysi
also
perform
appropri
order
assess
potenti
correl
measur
paramet
spearman
correl
also
perform
suitabl
statist
analys
carri
use
rsoftwar
rel
quantif
reveal
low
level
measur
cytokin
term
mrna
express
group
indistinguish
evalu
cytokin
p
respect
compar
cytokin
mrna
express
therapi
group
spite
overal
decreas
tendenc
express
significantli
decreas
po
group
p
except
cytokin
signific
chang
observ
cytokin
profil
either
group
versu
sc
group
p
respect
versu
po
group
p
respect
cat
group
show
minim
express
express
quantifi
one
cat
sc
group
two
po
group
end
therapi
cytokin
express
measur
one
cat
observ
sc
group
therefor
cytokin
express
set
zero
quantifi
cytokin
group
convers
po
group
minim
mrna
express
could
still
measur
end
therapi
express
neglig
group
therefor
result
chart
detail
two
cat
sc
group
one
cat
po
group
show
detect
mrna
express
two
cat
po
group
test
neg
express
detail
result
cytokin
shown
fig
concern
plasma
level
measur
cytokin
group
similar
p
p
respect
plasma
level
significantli
higher
sc
group
po
one
p
compar
begin
end
therapi
sc
group
signific
decreas
plasma
level
p
statist
differ
observ
plasma
level
group
p
p
respect
po
group
chang
observ
measur
plasmat
il
p
respect
detail
result
shown
fig
regard
primer
probe
use
provir
load
quantifi
fivb
system
cat
sc
group
po
group
fiva
system
work
success
cat
sc
group
po
group
assess
overal
chang
provir
load
result
subsystem
taken
togeth
shown
fig
statist
differ
group
therapi
p
also
timepoint
signific
posit
correl
could
observ
group
provir
load
clinic
condit
detail
data
refer
clinic
score
previous
publish
gil
et
al
gil
et
al
cc
sc
po
group
respect
therapi
statist
signific
increas
sc
group
p
contrast
po
group
although
provir
load
tend
increas
statist
signific
p
low
level
viremia
time
point
group
group
similar
p
detail
cat
sc
group
po
group
show
detect
viremia
detail
individu
valu
present
fig
sc
group
four
cat
undetect
viremia
level
remain
neg
therapi
three
cat
detect
viremia
two
becam
neg
one
reduc
po
group
seven
cat
undetect
viremia
three
remain
neg
four
becam
posit
therapi
consid
four
cat
test
posit
three
reduc
viremia
level
one
slightli
increas
despit
compar
level
begin
end
therapi
group
signific
differ
obtain
viremia
measur
p
po
sc
group
respect
contrast
seen
proviru
level
correl
note
viremia
level
clinic
health
statu
cc
sc
group
cc
po
group
also
correl
establish
viremia
proviru
time
point
cc
sc
group
cc
po
group
therapi
cc
sc
group
cc
po
group
studi
evalu
effect
two
distinct
protocol
blood
cytokin
profil
viremia
provir
load
cytokin
chosen
take
account
main
function
immun
system
consid
biomark
innat
acquir
immun
respons
therefor
measur
order
evalu
innat
proinflammatori
pathway
chosen
indic
pathway
activ
use
indic
respons
heterodimer
cytokin
compos
two
chain
trinchieri
et
al
measur
subunit
chosen
author
due
fact
subunit
avail
complementari
elisa
measur
even
quantif
possibl
mrna
express
low
anim
group
indistinguish
mrna
express
measur
cytokin
made
fig
mean
se
plasma
concentr
natur
fivinfect
cat
submit
two
differ
protocol
sc
refer
cat
treat
subcutan
licens
protocol
po
cat
receiv
oral
protocol
group
statist
similar
baselin
valu
except
concentr
higher
sc
group
po
group
group
sc
group
show
statist
signific
decreas
concentr
p
comparison
end
begin
therapi
sc
group
submit
licens
protocol
reliabl
posit
control
compar
begin
end
therapi
group
mark
differ
mrna
express
major
cytokin
although
decreas
tendenc
observ
decreas
signific
express
fivinfect
cat
oral
therapi
although
statist
signific
also
tend
decreas
anim
find
consist
overal
reduct
proinflammatori
pathway
cat
treat
oral
protocol
observ
sc
group
express
show
decreas
tendenc
therefor
also
licens
protocol
proinflammatori
pathway
innat
immun
respons
tend
reduc
correl
find
biomark
innat
immun
group
shown
licens
subcutan
therapi
associ
concurr
increas
app
opposit
oral
protocol
chang
app
profil
treat
cat
due
fact
strongli
involv
stimul
app
product
surpris
proinflammatori
pathway
tend
decreas
anim
possibl
explan
reli
fact
although
thought
main
induc
acut
phase
reaction
et
al
paltrinieri
cytokin
involv
phenomenon
recogn
app
sever
protect
function
ceron
et
al
hochepi
et
al
paltrinieri
petersen
et
al
steel
whitehead
variou
pathway
proinflammatori
stimuli
lead
product
therefor
seem
reason
state
paradox
increas
app
cat
evid
reduc
proinflammatori
stimuli
may
induc
mediat
duan
et
al
studi
need
fulli
understand
mechan
behind
observ
app
increas
cat
concern
mrna
level
measur
cytokin
chang
observ
either
group
mean
activ
cellular
immun
seem
way
therapi
provid
benefit
fivinfect
cat
observ
quantifi
cytokin
particular
undetect
major
anim
make
result
cytokin
neglig
method
nonetheless
mrna
express
allow
reason
quantif
activ
although
nonsignific
decreas
trend
note
protocol
mrna
express
closest
signific
oral
protocol
p
incident
may
partial
explain
benefit
seen
oral
therapi
recent
publish
studi
canin
atop
dermat
high
ratio
believ
contribut
disord
litzlbauer
et
al
therefor
fig
mean
se
provir
load
fiv
cat
receiv
two
differ
protocol
sc
refer
cat
treat
subcutan
licens
protocol
po
cat
receiv
oral
protocol
fig
individu
viremia
chang
fivinfect
cat
submit
two
protocol
cat
sc
group
receiv
subcutan
licens
protocol
cat
treat
oral
po
group
refer
timepoint
viremia
undetect
potenti
trend
reduc
mrna
express
result
demonstr
signific
impact
therapi
respons
fivinfect
cat
independ
chosen
protocol
concurr
mrna
express
monitor
plasma
level
also
measur
similarli
basal
valu
cytokin
express
group
similar
except
significantli
higher
anim
sc
group
po
group
explain
differ
factor
environ
cat
sc
group
live
catteri
wherea
cat
po
group
mainli
indoor
anim
less
exposur
cat
anoth
relev
factor
presenc
opportunist
infect
evid
sc
group
po
one
cat
anim
shelter
expect
respons
increas
due
constant
stimuli
concurr
infect
environment
challeng
howev
effect
therapi
assess
monitor
plasma
level
cytokin
therapi
cat
alter
live
condit
anticip
differ
baselin
relev
impact
result
nevertheless
chang
seen
plasma
level
statist
signific
overal
tendenc
consid
neglig
probabl
explain
high
individu
variabl
induc
slight
fluctuat
overal
result
cytokin
interestingli
plasma
level
significantli
reduc
sc
group
remain
stabl
cat
treat
oral
protocol
correl
result
mrna
express
profil
observ
sc
group
although
decreas
mrna
express
signific
induc
import
reduct
concurr
plasma
level
contrast
signific
decreas
note
mrna
express
cat
submit
oral
therapi
reflect
plasma
level
cytokin
explain
eventu
posttranscript
event
vogel
marcott
delay
translat
impair
direct
correl
mrna
express
concurr
plasma
level
cat
treat
oral
even
though
albeit
differ
result
suggest
cytokin
product
affect
fivinfect
cat
therapi
independ
protocol
appli
seem
reason
state
higher
pulsat
subcutan
dose
seem
effect
lower
continu
oral
therapi
reduc
proinflammatori
stimuli
fivinfect
cat
howev
continu
oral
therapi
also
alter
express
mean
immun
modul
protocol
retain
antiinflammatori
properti
result
reinforc
benefici
aspect
immunomodulatori
therapi
light
fact
basal
level
proinflammatori
cytokin
tend
increas
fivinfect
cat
lawrenc
et
al
provir
load
similar
group
expect
correl
establish
paramet
clinic
present
mean
cat
wors
condit
show
higher
level
proviru
previous
report
licens
protocol
induc
signific
chang
provir
load
et
al
howev
studi
found
signific
increas
provir
load
sc
group
increas
nonsignific
tendenc
also
note
oral
protocol
possibl
explan
find
lie
fact
group
lymphocyt
number
tend
increas
therapi
although
increas
within
refer
rang
may
explain
subsequ
increas
provir
load
especi
light
improv
clinic
condit
group
viremia
detect
small
proport
anim
group
surpris
studi
use
natur
infect
cat
unknown
durat
infect
chronic
fivinfect
cat
eventu
ceas
detect
viral
rna
due
viral
latenc
murphi
et
al
tomonaga
et
al
correl
establish
viremia
clinic
score
main
clinic
sign
symptomat
anim
therefor
like
due
opportunist
infect
rather
directli
induc
fiv
replic
suggest
benefici
effect
fivinfect
cat
unlik
relat
direct
antivir
action
fiv
viru
either
protocol
rather
improv
control
secondari
infect
addit
reduct
proinflammatori
pathway
clinic
trial
limit
must
state
even
group
differ
major
measur
variabl
cat
receiv
sc
group
live
catteryanim
shelter
cat
treat
oral
mainli
indoorown
cat
therefor
group
expos
differ
environment
human
stimuli
precis
determin
howev
recogn
result
set
baselin
valu
individu
control
cat
overal
tendenc
analyz
group
minim
limit
anoth
point
consid
cytokin
express
result
depend
blood
mrna
collect
extract
import
note
reliabl
measur
circul
mrna
difficult
rnaas
present
ubiquit
degrad
etheridg
et
al
furthermor
mrna
extract
effici
vari
accord
method
appli
affect
multipl
extern
variabl
blood
clot
sampl
condit
determin
qualiti
wong
et
al
author
knowledg
first
studi
report
cytokin
profil
base
blood
mrna
measur
natur
fivinfect
cat
consid
low
valu
obtain
reason
say
blood
mrna
seem
effect
plasma
level
even
vitro
studi
assess
aspect
immun
respons
roberttissot
et
al
concurr
evalu
stimul
pbmc
naturallyfiv
infect
cat
would
help
clarifi
data
interestingli
recent
studi
valid
microspher
immunoassay
detect
plasma
wood
et
al
perhap
near
futur
evalu
cytokin
profil
fiv
cat
easier
help
monitor
infect
cat
therapi
although
antivir
effect
fiv
seem
minor
fivinfect
cat
studi
help
enlarg
understand
role
immunomodul
cytokin
profil
anim
among
measur
cytokin
work
reveal
product
significantli
affect
fivinfect
cat
treat
subcutan
oral
protocol
high
puls
scheme
sc
protocol
lead
import
reduct
plasma
level
continu
lower
dose
oral
protocol
induc
decreas
express
although
suffici
reflect
signific
reduct
plasma
level
summari
acquir
immunerespons
name
pathway
found
major
mean
act
studi
main
action
seem
innat
immun
respons
reduc
proinflammatori
stimuli
antiinflammatori
action
part
justifi
observ
clinic
improv
induc
immunomodul
